Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Amilo-5MER in Healthy Volunteers
NCT05857215Phase 1Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amilo-5MER in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) (10 arms), sponsored by Galmed Pharmaceuticals. Primary endpoint: Safety and tolerability of amilo-5MER at 10 days. Started Mar 2021; status: completed.
02
Drugs
amilo-5MER
03
Conditions
inflammatory bowel disease (IBD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05857215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857215.